Novel approaches to female sexual dysfunction

被引:13
|
作者
Berman, LA [1 ]
Berman, JR [1 ]
Chhabra, S [1 ]
Goldstein, I [1 ]
机构
[1] Boston Univ, Med Ctr, Div Urol, Boston, MA 02215 USA
关键词
apomorphine; female pelvic anatomy; female sexual disorders; female sexual dysfunction; L-arginine; methyltestosterone; neurogenic mediators; oestrogen; phentolamine; prostaglandin E1; sildenafil; testosterone; yohimbine;
D O I
10.1517/13543784.10.1.85
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Female sexual dysfunction is age-related, progressive and highly prevalent, affecting 30 - 50% of American women. While there are emotional and relational elements to sexual function, it has become increasingly evident that female sexual dysfunction can occur secondary to medical problems and has an organic basis. A plethora of different female sexual dysfunctions exist and in order to obtain a greater understanding of the possible treatments for these problems, it is essential to have a strong knowledge base of female pelvic anatomy, the neurogenic mediators of female sexual response, the impact of hormones on female sexual function and the aetiologies of female sexual dysfunction. Currently, there are potential therapeutic options for the treatment of female sexual dysfunction and these options include both hormonal and pharmacological therapy. However, therapeutic agents may not prove to be enough and the ideal approach to female sexual dysfunction is thus a collaborative effort between therapists and physicians, which should include a complete medical and psychosocial evaluation, as well as inclusion of the partner or spouse in the evaluation and treatment process.
引用
收藏
页码:85 / 95
页数:11
相关论文
共 50 条
  • [21] Alternative therapies for male and female sexual dysfunction
    Aung, HH
    Dey, L
    Ran, V
    Yuan, CS
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2004, 32 (02): : 161 - 173
  • [22] Female sexual dysfunction: A primary care perspective
    Zakhari, Raymond
    JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS, 2009, 21 (09): : 498 - 505
  • [23] Therapeutic options for postmenopausal female sexual dysfunction
    Al-Azzawi, F.
    Bitzer, J.
    Brandenburg, U.
    Castelo-Branco, C.
    Graziottin, A.
    Kenemans, P.
    Lachowsky, M.
    Mimoun, S.
    Nappi, R. E.
    Palacios, S.
    Schwenkhagen, A.
    Studd, J.
    Wylie, K.
    Zahradnik, H. -P.
    CLIMACTERIC, 2010, 13 (02) : 103 - 120
  • [24] Therapy of female sexual dysfunction in multiple sclerosis
    Lew-Starowicz, Michal
    Rola, Rafal
    MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2013, 12 (02): : 166 - 174
  • [25] Epidemiology of female sexual dysfunction
    Palacios, Santiago
    Castano, Rosario
    Grazziotin, Alessandra
    MATURITAS, 2009, 63 (02) : 119 - 123
  • [26] Managing female sexual dysfunction
    Arthur, Sarah S.
    Dorfman, Caroline S.
    Massa, Lisa A.
    Shelby, Rebecca A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (08) : 359 - 365
  • [27] Managing female sexual dysfunction
    Buster, John E.
    FERTILITY AND STERILITY, 2013, 100 (04) : 905 - 915
  • [28] FLIBANSERIN FOR FEMALE SEXUAL DYSFUNCTION
    Reviriego, C.
    DRUGS OF TODAY, 2014, 50 (08) : 549 - 556
  • [29] Female Sexual Dysfunction: Is It a Treatable Disease?
    Justin Houman
    Tom Feng
    Karyn S. Eilber
    Jennifer T. Anger
    Current Urology Reports, 2016, 17
  • [30] Female sexual dysfunction: A potential minefield
    Prabhu, Smitha S.
    Hegde, Snigdha
    Sareen, Suhani
    INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES AND AIDS, 2022, 43 (02) : 128 - 134